RBC Capital Reiterates Outperform on Karyopharm Therapeutics, Maintains $3 Price Target
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Brian Abrahams has reiterated an Outperform rating on Karyopharm Therapeutics (NASDAQ:KPTI) and maintained a $3 price target.
August 07, 2024 | 4:23 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
RBC Capital analyst Brian Abrahams has reiterated an Outperform rating on Karyopharm Therapeutics and maintained a $3 price target.
The reiteration of an Outperform rating and the maintenance of a $3 price target by RBC Capital is a positive signal for investors, suggesting confidence in the company's future performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100